These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31082851)

  • 1. Cardiotoxicity of HER2-targeted therapies.
    Copeland-Halperin RS; Liu JE; Yu AF
    Curr Opin Cardiol; 2019 Jul; 34(4):451-458. PubMed ID: 31082851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
    Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
    Jerusalem G; Lancellotti P; Kim SB
    Breast Cancer Res Treat; 2019 Sep; 177(2):237-250. PubMed ID: 31165940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
    Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.
    Dent SF; Morse A; Burnette S; Guha A; Moore H
    Curr Oncol Rep; 2021 Aug; 23(11):128. PubMed ID: 34453232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?
    Kimmick G; Dent S; Klem I
    Curr Treat Options Cardiovasc Med; 2019 May; 21(6):30. PubMed ID: 31152324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
    Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
    Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
    Rygiel K
    Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity in HER2-positive breast cancer patients.
    Gonciar D; Mocan L; Zlibut A; Mocan T; Agoston-Coldea L
    Heart Fail Rev; 2021 Jul; 26(4):919-935. PubMed ID: 33405000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction.
    Zhang I; Barac A
    Curr Oncol Rep; 2022 Aug; 24(8):1063-1070. PubMed ID: 35362825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer treatment-induced cardiotoxicity.
    Martel S; Maurer C; Lambertini M; Pondé N; De Azambuja E
    Expert Opin Drug Saf; 2017 Sep; 16(9):1021-1038. PubMed ID: 28697311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review.
    Jafari L; Akhter N
    Breast Cancer Res Treat; 2021 Apr; 186(2):295-303. PubMed ID: 33481134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.